AAAAAA
Results:
1-11
|
Results: 11
Authors:
Sparidans, RW
Rosing, H
Hillebrand, MJX
Lopez-Lazaro, L
Jimeno, JM
Manzanares, I
van Kesteren, C
Cvitkovic, E
van Oosterom, AT
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man, ANTI-CANC D, 12(8), 2001, pp. 653-666
Authors:
Sparidans, RW
Stokvis, E
Jimeno, JM
Lopez-Lazaro, L
Schellens, JHM
Beijnen, JH
Citation: Rw. Sparidans et al., Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F, ANTI-CANC D, 12(7), 2001, pp. 575-582
Authors:
Luber-Narod, J
Smith, B
Grant, W
Jimeno, JM
Lopez-Lazaro, L
Faircloth, GT
Citation: J. Luber-narod et al., Evaluation of the use of in vitro methodologies as tools for screening newcompounds for potential in vivo toxicity, TOX VITRO, 15(4-5), 2001, pp. 571-577
Authors:
Taamma, A
Misset, JL
Riofrio, M
Guzman, C
Brain, E
Lazaro, LL
Rosing, H
Jimeno, JM
Cvitkovic, E
Citation: A. Taamma et al., Phase I and pharmacokinetic study of ecteinaseidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors, J CL ONCOL, 19(5), 2001, pp. 1256-1265
Authors:
Nuijen, B
Bouma, M
Talsma, H
Manada, C
Jimeno, JM
Lopez-Lazaro, L
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F, DRUG DEV IN, 27(8), 2001, pp. 767-780
Authors:
Nuijen, B
Bouma, M
Manada, C
Jimeno, JM
Lazaro, LL
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices, INV NEW DR, 19(4), 2001, pp. 273-281
Authors:
van Kesteren, C
Cvitkovic, E
Taamma, A
Lopez-Lazaro, L
Jimeno, JM
Guzman, C
Mathot, RAA
Schellens, JHM
Misset, JL
Brain, E
Hillebrand, MJX
Rosing, H
Beijnen, JH
Citation: C. Van Kesteren et al., Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study, CLIN CANC R, 6(12), 2000, pp. 4725-4732
Authors:
Nuijen, B
Bouma, M
Manada, C
Jimeno, JM
Schellens, JHM
Bult, A
Beijnen, JH
Citation: B. Nuijen et al., Pharmaceutical development of anticancer agents derived from marine sources, ANTI-CANC D, 11(10), 2000, pp. 793-811
Authors:
Sparidans, RW
Kettenes-van den Bosch, JJ
van Tellingen, O
Nuyen, B
Henrar, REC
Jimeno, JM
Faircloth, G
Floriano, P
Rinehart, KL
Beijnen, JH
Citation: Rw. Sparidans et al., Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4'-hydrazino-2-stilbazole, J CHROMAT B, 729(1-2), 1999, pp. 43-53
Authors:
Sparidans, RW
Henrar, REC
Jimeno, JM
Faircloth, G
Floriano, P
Beijnen, JH
Citation: Rw. Sparidans et al., Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection, J CHROMAT B, 726(1-2), 1999, pp. 255-260
Authors:
Hendriks, HR
Fiebig, HH
Giavazzi, R
Langdon, SP
Jimeno, JM
Faircloth, GT
Citation: Hr. Hendriks et al., High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer, ANN ONCOL, 10(10), 1999, pp. 1233-1240
Risultati:
1-11
|